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Stroke has a deleterious impact on quality of life. However, it is less well known if stroke lesions in 
different brain regions are associated with reduced quality of life (QoL). We therefore investigated 
this association by multivariate lesion‑symptom mapping. We analyzed magnetic resonance imaging 
and clinical data from the WAKE‑UP trial. European Quality of Life 5 Dimensions (EQ‑5D) 3 level 
questionnaires were completed 90 days after stroke. Lesion symptom mapping was performed 
using a multivariate machine learning algorithm (support vector regression) based on stroke lesions 
22–36 h after stroke. Brain regions with significant associations were explored in reference to white 
matter tracts. Of 503 randomized patients, 329 were included in the analysis (mean age 65.4 years, 
SD 11.5; median NIHSS = 6, IQR 4–9; median EQ‑5D score 90 days after stroke 1, IQR 0–4, median 
lesion volume 3.3 ml, IQR 1.1–16.9 ml). After controlling for lesion volume, significant associations 
between lesions and EQ‑5D score were detected for the right putamen, and internal capsules of both 
hemispheres. Multivariate lesion inference analysis revealed an association between injuries of the 
cortico‑spinal tracts with worse self‑reported quality of life 90 days after stroke in comparably small 
stroke lesions, extending previous reports of the association of striato‑capsular lesions with worse 
functional outcome. Our findings are of value to identify patients at risk of impaired QoL after stroke.
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Abbreviations
DWI  Diffusion-weighted imaging
EQ-5D  European Quality of Life 5 Dimensions
FLAIR  Fluid-attenuated inversion recovery
FEW  Familywise error correction
IQR  Inter-quartile range
LSM  Lesion-symptom mapping
MCA  Middle cerebral artery
MNI  Montreal Neurological Institute
mRS  Modified Rankin Scale
NIHSS  National Institutes of Health Stroke Scale
PROMs  Patient reported outcome measures
QoL  Quality of life
SD  Standard deviation
SVR  Support vector regression
Ischemic stroke affects health-related quality of life of patients in various domains beyond impairments captured 
by scales such as the National Institutes of Health Stroke Scale (NIHSS) or modified Rankin Scale (mRS)1,2. In 
recent years, the importance of patient reported outcome measures (PROMs) in stroke care and research has 
been addressed, as these capture the patient’s own perspective on quality of life and are therefore of relevance to 
promote shared decision-making, facilitate personalized health care and ultimately improve patients well-being 
after  stroke3,4. Several questionnaires and scores are available to operationalize quality of life (QoL) after stroke. 
The European Quality of Life 5 Dimensions (EQ-5D) represents one of the most widely used instruments in 
clinical studies and population surveys, and includes five key dimensions of self-reported QoL: mobility, self-
care, usual activities, pain or discomfort and anxiety or  depression5.
Stroke lesion location exerts a major impact on the degree of clinical deficits, recovery and functional 
 outcome6,7. Anatomical localization of stroke lesions in strategic brain areas results in proportionally higher 
scores on the mRS and is therefore of interest to predict stroke severity beyond traditional imaging markers such 
as lesion  volume6. In addition, mapping clinical scales to (eloquent) brain areas may improve understanding of 
the underlying structure–function relationship. With regard to the EQ-5D as a short form of PROM, associa-
tions between stroke lesion location and QoL measures remain largely unexplored. We therefore investigated 
the impact of stroke lesion location on the EQ-5D based on clinical and imaging data from the WAKE-UP trial, 
a multicenter-randomized, double-blind, placebo-controlled trial of MRI-based intravenous thrombolysis in 
patients with unknown onset stroke. We applied a voxel-wise, multivariate, lesion-symptom mapping (LSM) 
technique based on a supervised machine learning algorithm (support vector regression, SVR) to account for nui-
sance variables and lesion patterns beyond single voxels that cannot be resolved by traditional, mass-univariate 
 models8. We hypothesized that by this approach, we would identify brain areas responsible for sensory, motor 
and affective functions that feature prominently in the EQ-5D.
Results
Descriptive statistics. Of 503 patients randomized in WAKE-UP, EQ-5D scores were available for 452 
patients. Of patients with missing EQ-5D (N = 51), 13 died and for N = 38, EQ-5D was not available. Stroke 
lesion segmentation and registration to MNI was successful in 349 (of 452) patients on follow-up imaging 
22–36 h after randomization. Reasons for missing data (n = 103) were: missing imaging (either FLAIR or DWI) 
in 21 patients, hemorrhagic transformation (n = 23), CT imaging on follow-up (n = 20) and insufficient imaging 
quality (n = 39). Mean age of the 349 included patients was 65.4 years (SD 11.5), 228 (65.3%) patients were male, 
median NIHSS score was 6 (IQR 4–9). 90 days after stroke, median EQ-5D score at 90 days was 1 (IQR 0–4) 
and median mRS score 2 (IQR 1–3). Median DWI stroke lesion volume was 3.3 ml (IQR 1.1 ml–16.9 ml, mean 
17.3 ± 33.3 ml, minimum 0.02 ml, maximum 233 ml). Stroke lesions were located in the left hemisphere in 190 
patients, right hemisphere in 136 and in both hemispheres in 23.
Figure 1 illustrates the distributions of the EQ-5D sum score and individual subscores stratified by affected 
hemisphere. Whereas the majority of patients reported few complaints in individual subscores (0 points), mod-
erate or severe problems (1 or 2 points) were reported for example in up to 49% of patients regarding the 
performance of usual activities (EQ-5D subscore 3). There was a significant correlation between higher EQ-5D 
scores 90 days after stroke with higher mRS scores (Spearman r = 0.742, p < 0.001). 20 patients were excluded 
from SVR-LSM due to non-overlap of lesioned voxels with the minimum lesion cutoff mask. Figure 2 displays 
the distribution of stroke lesions of patients that were finally included by SVR-LSM (n = 329) overlaid on an 
MNI standard space template.
SVR LSM detected three clusters containing more than 50 lesioned voxels associated with higher sum scores 
of EQ-5D, i.e., worse self-reported QoL (see Table 1). Of those, one cluster reached the FWE correction p-value 
(p < 0.05) and was located in the right corticospinal tract at the level of the internal capsule and corona radiata. As 
illustrated in Fig. 3, the remaining two clusters with > 50 voxels were located at the putamen, corticospinal tract 
and uncinate fasciculus. Details are listed in Table 1. Model quality measures were implemented as previously 
 described9 and indicated sufficient prediction accuracy and pattern reproducibility with values comparable to 
previous analogous applications of SVR-LSM methods (see Supplemental Table S2 and Fig. S1)10. Analysis of 
lesion cluster locations in reference to white matter fibers by the BCB (Brain Connectivity and Behavior) Toolkit 
(Foulon et al.11; http:// www. toolk it. bcblab. com) revealed a high certainty of overlap voxels associated with high 
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EQ5D scores with the corticospinal tract, pontine and thalamic projections and superior longitudinal fasciculus, 
among others (Table 2).
Discussion
The aim of this study was to explore lesion-symptom relationships for self-reported quality of life after stroke. As 
a main result, we demonstrate the association of higher EQ-5D values 90 days after stroke with lesions located in 
deep grey matter and white matter structures involved in motor functions, such as the basal ganglia and cortico-
spinal tracts of both hemispheres.
Up to now, few studies have investigated the association between lesion location and self-reported measures 
of QoL after stroke. Grouping lesions by imaging-informed etiology, a previous study reported hemorrhages, 
territorial or supratentorial strokes to be associated with subsequent lower QoL 6 months after stroke compared 
to ischemic, infratentorial or lacunar  strokes12. Except for domains involving speech, there was no clear relation-
ship between stroke laterality and  QoL12. In contrast, an analysis investigating 229 patients with minor stroke 
symptoms (NIHSS ≤ 5), found that stroke lesions located in the brainstem and subcortical strokes were associated 
with lower self-reported QoL compared to stroke lesions involving the cerebral  cortex13. Our findings extend 
observations from these studies by providing high-resolution anatomical locations of lesions impacting quality 
of life measured by the EQ-5D in a large cohort of acute stroke patients.
In our main analysis, worse QoL after stroke measured by EQ-5D was primarily associated with stroke lesions 
located at the corticospinal tract at the level of the internal capsule (Table 1, Fig. 3). Although the cluster located 
at the left cortico-spinal tract did not achieve full FWE correction for cluster extent (p = 0.062), we would not 
consider this as a false-positive result given the close proximity to the predefined statistical threshold (p < 0.05), 
anatomical plausibility, cluster size and the cluster’s survival of voxel-wise permutation testing performed by 
SVR-LSM. These findings are plausible given the fact that motor functions influence at least three of five domains 
captured in the EQ-5D, specifically mobility, self-care and usual daily  activities5. In line with this observation, 
high scores on common stroke severity scales capturing impairment of motor function such as the NIHSS and 
mRS have been shown to contribute significantly to reduced self-reported quality of life measured by the EQ-5D 
and similar  instruments14–17. In our study, worse clinical outcome as measured by the mRS was also associated 
with lower QoL as measured by the EQ-5D. From the perspective of lesion-symptom relationship inference, 
higher mRS scores 3 months after stroke have previously been shown to be associated with lesions located in the 
corticospinal tract similar to our current findings from mapping the EQ-5D7.
Figure 1.  Histograms demonstrating the distribution of EQ-5D sum scores and subscores. Higher scores 
relate to lower self-reported measures of quality of life. Affected hemisphere is indicated by color (both 
hemispheres = red, left hemisphere = green, right hemisphere = blue).
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In addition to mapping anatomical location, we explored the relevance of brain areas identified by lesion-
symptom inference leading to lower EQ-5D in reference to an atlas of white matter fiber tracts (Table 2). As 
expected, this showed involvement of white matter tracts facilitating motor functions such as the corticospinal 
and fronto-striatal tract as well as pontine projections. However, this indirect analysis also revealed a potential 
involvement of various fiber bundles traversing inter- and intra-hemispheric brain regions such as the superior 
longitudinal fasciculus or corpus callosum. These findings motivate future investigations of structural discon-
nection and suggest more complex contributions of structural connectivity beyond classical motor pathways 
contributing to quality of live after stroke.
We assessed self-reported QoL using the EQ-5D questionnaire, which is a prominent and widely applied 
scales in stroke  care14,18–20. However, questionnaires that capture aspects of QoL in more detail then the E5QD 
are available specifically in stroke populations like the Stroke Impact Scale (SIS) and Stroke-Specific Quality of 
Life Scale (SS-QoL)19. Although our findings are not directly generalizable to results obtained by these more 
specific instruments, physical disability features prominently in almost all patient-reported measures and we 
would therefore argue that our findings are valid regarding the self-perceived and -reported information on 
quality of life in our  patients3.
Figure 2.  Overlay lesion plot of stroke lesions from all patients (n = 329) in radiological convention mapped 
onto the Montreal Neurological Institute (MNI) template. Overlays are thresholded to show lesions present 
in at least 10 individuals as included in the lesion-symptom mapping analysis. The color bar indicates lesion 
frequency across all patients. MNI coordinates of each transverse section (z axis) are indicated in white numbers 
above the slices.
Table 1.  Results of SVR lesion-symptom mapping for the EQ-5D sum scores. Clusters with N > 50 significant 
voxels after permutation based on a voxel-wise threshold of p < 0.005 are shown. Results are listed by increasing 
cluster wise FWE p-value. MNI coordinates are given at the center location of each cluster and the anatomical 
regions. *p < 0.05 resulting from FWE correction.
Cluster number and color 
(Fig. 3)
Cluster wise FWE corrected 
p-value Number of voxels Anatomical location
MNI center coordinates 
(X, Y, Z)
1, Red 0.0363* 717 Right corticospinal tract 27.9; − 13; 20.1
2, Green 0.0624 444 Left corticospinal tract − 26.4; − 12.8; 20.7
3, Blue 0.2981 53 Right putamenRight uncinate fascicle 29.7; − 0.2; − 8.2
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:13490  | https://doi.org/10.1038/s41598-021-92865-x
www.nature.com/scientificreports/
Strengths of our study are the inclusion of clinical data from patients from a large, prospective clinical stroke 
trial, definition of lesions based on MRI and the use of an innovative multivariate lesion-symptom mapping 
approach that is superior to traditional mass-univariate LSM methods.
In terms of limitations, PROMs generally tend to under-represent severely affected patients and patients 
with deficits that restrain them from participating in a questionnaire, also there might be a bias towards patients 
presenting with motor deficits and clinically not-apparent or improved language and visuo-spatial deficits. 
Figure 3.  Results of SVR lesion-symptom mapping for the EQ-5D sum scores illustrated on a brain template 
in MNI standard space oriented in radiological convention. Three clusters with N > 50 significant voxels after 
permutation based on a threshold of p < 0.005 are shown. Clusters are color-coded to identify p-values after 
cluster-wise FWE correction (p = 0.036 [red]; p = 0.062 [green]; p = 0.298 [blue]). See also Table 1 for statistical 
and anatomical details. MNI coordinates of each transverse section (z axis) are shown.
Table 2.  Certainty of non-zero overlap between the union of clusters, if they contained > 50 voxels and were 
identified by SVR-LSM for the EQ-5D sum score (cf. Table 1), and anatomically pre-defined white matter 
tracts (implemented in the Tractotron software, standalone version of the BCB Toolkit: Foulon et al.11; http:// 
www. toolk it. bcblab. com). Displayed are only tracts which contain, with a probability > 90%, at least one voxel 
associated with higher EQ-5D scores.
Tract Right hemisphere (%) Left hemisphere (%)
Corticospinal tract 100 100
Fronto-striatal tract 100 100
Pontine projections 100 100
Superior longitudinal fasciculus II 97 98
Superior longitudinal fasciculus III 100 99
Anterior thalamic projections 96 98
Frontal aslant tract – 100
Corpus callosum 90 100
Inferior fronto-occipital fasciculus 100 100
Uncinate fasciculus 100 98
Anterior commissure 96 –
Fronto-insular tract 4 96 –
Fronto-insular tract 5 100 –
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Unavailable questionnaires in this study might have influenced the results. As three out of five categories of the 
EQ-5D relate to motor functions, other aspects of QoL might be rather underrepresented by the questionnaire. 
As an additional limitation, lesion distribution in WAKE-UP, similar to other stroke trials, may have biased our 
results towards brain functions located in brain areas supplied by the middle cerebral artery (MCA). Therefore, 
lesion-symptom inference for QoL regarding stroke lesions located in brain areas such as the frontal cortex or 
areas supplied by the posterior arterial circulations, have to be explored in future studies. Moreover, the median 
lesion size was rather small compared to a “traditional” stroke patient cohort, the findings of this study can hence 
not be directly transferred to larger sized stroke lesions. Clinical factors like hemiparesis were not included in 
the analysis, therefore a possible influence of these could not be commented on.
Summary
In summary, multivariate lesion inference analysis revealed an association of comparably small acute stroke 
lesions in the internal capsule with worse self-reported quality of life 90 days after stroke. These findings extend 
previous reports of the association of striato-capsular lesions with worse functional outcome of stroke. Our find-
ings are of value to identify stroke patients at risk of impaired QoL and illustrate dependencies of the EQ-5D as 
a popular PROM on anatomical localization of brain injury.
Methods
Study design. We analyzed clinical and imaging data from the WAKE-UP trial (ClinicalTrials.gov number, 
NCT01525290), a multicenter, randomized, double-blind, placebo-controlled trial of MRI-based intravenous 
thrombolysis in patients with unknown onset stroke. The detailed trial protocol and the results of the WAKE-UP 
trial have been published  previously21. Briefly summarized, patients presenting with signal change on Diffusion 
weighted imaging (DWI) but no visible abnormality on T2-fluid-attenuated inversion recovery (FLAIR) were 
selected on the basis of probable stroke onset in the preceding 4.5 h and randomized to receiving alteplase or 
placebo. Written informed consent was provided according to national and local regulations by patients or their 
legal representatives with an exception from explicit informed consent in emergency circumstances in some 
countries. All methods were carried out in accordance with relevant guidelines and regulations. All experimen-
tal protocols were approved by the ethics committee of the Hamburg chamber of physicians and Federal Institute 
for Drugs and Medical Devices (BfArM) as regulatory authority.
For this secondary analysis, we selected only patients included in the WAKE-UP trial for whom both MRI 
data and a completed European Quality of Life 5 Dimensions (EQ-5D) 3 level form 90 days after stroke were 
available. Imaging data were collected from MRI performed after randomization, 22–36 h after admission. Due 
to incorrect segmentation in the presence of larger areas with signal loss, we excluded patients with MR images 
of insufficient quality and those with hemorrhagic transformation of stroke. We collected clinical data from 
WAKE-UP, including patient age at symptom onset, sex, randomization result (alteplase or placebo), NIHSS on 
admission, and mRS score 90 days after stroke.
Self-reported quality of life was assessed 90 days after stroke via the EQ-5D-3L  questionnaire5. It consists 
of five subscores (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each featuring 
three levels of severity of impairment (Supplementary Table S1). Individual subscores were added to calculate 
the EQ-5D sum scores.
Descriptive statistics of clinical and imaging data are provided as mean, median and standard deviation (SD) 
or interquartile range (IQR), where appropriate. A Spearmann rank-order correlation was applied to assess the 
association between mRS and EQ-5D at 90 days after stroke. Statistical significance was defined as p < 0.05. The 
statistical analysis was performed in R (v3.1.4).
Image analysis. Stroke lesions were segmented and lesion volumes quantified as described  previously22. In 
summary, imaging data were analyzed by dedicated software developed for the WAKE-UP trial (Stroke Quan-
tification Tool, SONIA) performing registration and semi-automated stroke lesion segmentation based on an 
apparent diffusion coefficient (ADC) threshold of 620  mm2/s. After quality control of the segmentation and 
manual correction where necessary, lesion volumes were calculated on binary lesion maps in native space. After-
wards, lesion masks were transformed to Montreal Neurological Institute (MNI) space by linear and non-linear 
registrations based on FLAIR  data23. All lesions masked were checked for correct segmentation and registration 
into MNI-space by two raters experienced in stroke MR imaging (A. K., B. C.). Imaging data with erroneous 
registration were excluded from analysis.
Lesion symptom mapping. Multivariate lesion-symptom mapping was conducted using support vector 
regression (SVR), a supervised learning algorithm that extends support vector machines and allows for regres-
sion involving continuous  variables24. SVR-LSM can be applied for lesion-symptom inference with superior sen-
sitivity and specificity compared to traditional mass-univariate lesion-symptom methods, taking into account 
lesion patterns distributed over separate  voxels8. SVR was conducted using a publicly available SVR lesion symp-
tom mapping toolbox (SVR-LSM, available at https:// github. com/ atdem arco/ svrls mgui) applying functionali-
ties of the Statistics and Machine Learning Toolbox within MATLAB (MATLAB 2019b, The MathWorks, Inc., 
Natick, Massachusetts, United States)25. In summary, SVR creates regression models assigning a “feature weight” 
to each voxel based on its lesion status and a behavioral variable. Multiple random permutations of the SVR on 
behavioral data are then performed to reveal statistically significant associations based on pre-defined statistical 
thresholds. For our analysis, only voxels with a minimum of 10 overlapping lesions were included for statistical 
testing in line with previous applications in similar datasets. We conducted the SVR-LSM analysis for the sum 
score of EQ-5D with higher values signifying lower quality of life. The SVR-LSM toolbox further allows for 
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addressing lesion volume as a nuisance variable. Prior to SVR, lesion volumes were regressed out of lesion data 
on a voxelwise basis and behavioral data since we found stroke volumes to be correlated with the EQ-5D. We 
applied an epsilon-SVR using a non-linear, radial basis function kernel analogous to the original publication 
found to be valid in comparable stroke imaging  datasets25. A 20-fold cross-validated, Bayesian optimization 
with 200 iterations as implemented in Matlab (bayesopt) was applied to establish the optimal SVR hyperparam-
eters related to our dataset. SVR was subsequently run using optimized hyperparameters with 10,000 permuta-
tions and a voxelwise threshold of p < 0.005 to detect voxels with significant association with clinical behavior. 
Co-localized voxels were then grouped into clusters and an additional family wise error (FWE) correction of 
p < 0.05 was applied. In an exploratory approach, we also report the presence and location of clusters consisting 
of > 50 contiguous voxels, but not meeting full FWE correction. Anatomical location of all clusters was deter-
mined according to the Harvard–Oxford Cortical and Subcortical Structural Atlas and the Juelich Histological 
 Atlas26,27. In addition, we explored the anatomical location of brain areas with significant lesion-symptom asso-
ciations in relation to white matter fiber bundles. Therefore, we mapped clusters of significant voxels resulting 
from SVR-LSM onto a white matter atlas. We applied the Tractotron toolbox (standalone version) of the BCB 
Toolkit (Foulon et al.11; http:// www. toolk it. bcblab. com), which comprises a probabilistic white matter tractogra-
phy atlas derived from 47 healthy individuals. For each fibre tract, we quantified the certainty that it intersects a 
cluster of voxels by extracting, for each voxel in the cluster, the probability of it belonging to the fibre tract, and 
then taking the maximum over all voxels in the  cluster11,28,29. For our analysis, we report fiber tracts that intersect 
significant clusters after SVR-LSM with a certainty > 90%.
Received: 27 January 2021; Accepted: 15 June 2021
References
 1. van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J. & van Gijn, J. Interobserver agreement for the assessment of 
handicap in stroke patients. Stroke 19, 604–607 (1988).
 2. Kasner, S. E. Clinical interpretation and use of stroke scales. Lancet Neurol. 5, 603–612 (2006).
 3. Reeves, M. et al. Patient-reported outcome measures (PROMs) for acute stroke: Rationale, methods and future directions. Stroke 
49, 1549–1556 (2018).
 4. Porter, M. E. What is value in health care?. N. Engl. J. Med. 363, 2477–2481 (2010).
 5. Rabin, R. & De Charro, F. EQ-5D: A measure of health status from the EuroQol Group. Ann. Med. 33, 337–343 (2001).
 6. Menezes, N. M. et al. The real estate factor: Quantifying the impact of infarct location on stroke severity. Stroke 38, 194–197 (2007).
 7. Cheng, B. et al. Influence of stroke infarct location on functional outcome measured by the modified rankin scale. Stroke 45, 
1695–1702 (2014).
 8. Mah, Y. H., Husain, M., Rees, G. & Nachev, P. Human brain lesion-deficit inference remapped. Brain 137, 2522–2531 (2014).
 9. DeMarco, A. & Turkeltaub, P. A multivariate lesion symptom mapping toolbox and examination of lesion-volume biases and cor-
rection methods in lesion-symptom mapping. Brain 21, 2461–2467 (2006).
 10. Mandal, A. S. et al. Brain structures and cognitive abilities important for the self-monitoring of speech errors. Neurobiol. Lang. 1, 
1–52 (2020).
 11. Foulon, C. et al. Advanced lesion symptom mapping analyses and implementation as BCBtoolkit. Gigascience. 7(3), 1–17 (2018).
 12. de Haan, R. J., Limburg, M., Van der Meulen, J. H., Jacobs, H. M. & Aaronson, N. K. Quality of life after stroke: Impact of stroke 
type and lesion location. Stroke 26, 402–408 (1995).
 13. Lin, C. et al. Infarct location is associated with quality of life after mild ischemic stroke. Int. J. Stroke. 13, 824–831 (2018).
 14. Yeoh, Y. S. et al. Can acute clinical outcomes predict health-related quality of life after stroke: A one-year prospective study of 
stroke survivors. Health Qual. Life Outcomes. 16, 1–9 (2018).
 15. Abubakar, S. A. & Isezuo, S. A. Health related quality of life of stroke survivors: Experience of a stroke unit. Int. J. Biomed. Sci. 8, 
183–187 (2012).
 16. Rangaraju, S., Haussen, D., Nogueira, R. G., Nahab, F. & Frankel, M. Comparison of 3-month stroke disability and quality of life 
across modified rankin scale categories. Interv. Neurol. 6, 36–41 (2017).
 17. Hankey, G. J. et al. Rate, degree, and predictors of recovery from disability following ischemic stroke. Neurology 68, 1583–1587 
(2007).
 18. Opara, J. A. & Jaracz, K. Quality of life of post-stroke patients and their caregivers. J. Med. Life. 3, 216–220 (2010).
 19. Carod-Artal, F. J. & Egido, J. A. Quality of life after stroke: The importance of a good recovery. Cerebrovasc. Dis. 27, 204–214 (2009).
 20. Thingstad, P. et al. The Norwegian Cognitive impairment after stroke study (Nor-COAST): Study protocol of a multicentre, pro-
spective cohort study. BMC Neurol. 18, 1–10 (2018).
 21. Thomalla, G. et al. MRI-guided thrombolysis for stroke with unknown time of onset. N. Engl. J. Med. 379, 611–622 (2018).
 22. Cheng, B. et al. Quantitative signal intensity in fluid-attenuated inversion recovery and treatment effect in the WAKE-UP trial. 
Stroke 51, 209–215 (2020).
 23. Mazziotta, J. et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping 
(ICBM). Philos. Trans. R. Soc. B 356, 1293–1322 (2001).
 24. Zhang, Y., Kimberg, D. Y., Coslett, H. B., Schwartz, M. F. & Wang, Z. Multivariate lesion-symptom mapping using support vector 
regression. Hum. Brain Mapp. 35, 5861–5876 (2014).
 25. DeMarco, A. T. & Turkeltaub, P. E. A multivariate lesion symptom mapping toolbox and examination of lesion-volume biases and 
correction methods in lesion-symptom mapping. Hum. Brain Mapp. 39, 4169–4182 (2018).
 26. Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions 
of interest. Neuroimage 31, 968–980 (2006).
 27. Eickhoff, S. B. et al. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuro-
image 25, 1325–1335 (2005).
 28. Rojkova, K. et al. Atlasing the frontal lobe connections and their variability due to age and education: A spherical deconvolution 
tractography study. Brain Struct Funct 221, 1751–1766 (2016).
 29. De Schotten, M. T. et al. Damage to white matter pathways in subacute and chronic spatial neglect: A group study and 2 single-case 
studies with complete virtual “in vivo” tractography dissection. Cereb. Cortex. 24, 691–706 (2014).
8
Vol:.(1234567890)
Scientific Reports |        (2021) 11:13490  | https://doi.org/10.1038/s41598-021-92865-x
www.nature.com/scientificreports/
Acknowledgements
The authors thank the WAKE-UP investigators for the enabling of the WAKE-UP study.
Author contributions
A.K. wrote the main manuscript text and B.C. supervised the analysis and the formation of the manuscript, 
A.d.M. provided the toolbox and supervised the analysis. All authors took part in the collection of data. All 
authors reviewed the manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Competing interests 
AK reports grants from European Union 7th Framework Program during the conduct of the study. ADM has 
nothing to disclose. CM has nothing to disclose. AW has nothing to disclose. ES has nothing to disclose. ME 
reports grants from European Union 7th Framework Program during the conduct of the study. THC has noth-
ing to disclose. MEn reports grants from European Union 7th Framework Program during the conduct of the 
study, grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi 
Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Covidien, Novartis, all outside the submitted work. JBF reports 
grants from European Union 7th Framework Program during the conduct of the study and personal fees from 
Bioclinica, BMS, Biogen, Artemida, Cerevast, Guerbet, EISAI and Nicolab outside the submitted work. JF has 
nothing to disclose. IG reports grants from European Union 7th Framework Program during the conduct of the 
study. JP has nothing to disclose. VT reports grants from European Union 7th Framework Program and personal 
fees and non-financial support from Boehringer Ingelheim, Pfizer/BMS, Bayer, Sygnis, Amgen and Allergan 
outside the submitted work. RL reports no personal fees, but institutional support for consultancy and speaker 
fees from Bayer, Boehringer-Ingelheim, Genentech, Ischemaview, Medtronic and Occlutech outside the submit-
ted work. KWM reports grants from European Union 7th Framework Program during the conduct of the study, 
personal fees and non-financial support from Boehringer Ingelheim outside the submitted work, personal fees 
from Boehringer Ingelheim, Bayer, Daiichi Sankyo and ReNeuron outside the submitted work. NN has nothing 
to disclose. SP reports grants from European Union 7th Framework Program during the conduct of the study. 
CZS reports grants from Novo Nordisk Foundation and personal fees from Bayer outside the submitted work. CG 
reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from 
AMGEN, Bayer Vital, BMS, Boehringer Ingelheim, Sanofi Aventis, Abbott, and Prediction Biosciences outside 
the submitted work. GT reports grants from European Union 7th Framework Program during the conduct of 
the study, personal fees from Acandis, Boehringer Ingelheim, BMS/Pfizer, Stryker, Daiichi Sankyo, grants and 
personal fees from Bayer, grants from Corona Foundation, German Innovation Fonds and Else Kroener Frese-
nius Foundation outside the submitted work. BC reports grants from European Union 7th Framework Program 
during the conduct of the study and personal fees from Bayer Vital and Abbott, all outside the submitted work.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 92865-x.
Correspondence and requests for materials should be addressed to A.K.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
